source
- Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectationsMedicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
- Specialized logistics critical for delivering next-generation cell and gene therapiesThe article explains that personalized medicines such as cell and gene therapies are transforming treatment for rare diseases and cancers. Unlike conventional drugs, these therapies are often made…